Deep brain stimulation for psychostimulant use disorders

Safe and effective therapeutics for psychostimulant use disorders remain elusive. Deep brain stimulation (DBS), which is FDA-approved for other indications, is a promising candidate for treating severe substance use disorders. We examine the clinical and preclinical evidence for DBS of the nucleus a...

Full description

Saved in:
Bibliographic Details
Published inJournal of Neural Transmission Vol. 131; no. 5; pp. 469 - 473
Main Authors Swinford-Jackson, Sarah E., Pierce, R. Christopher
Format Journal Article
LanguageEnglish
Published Vienna Springer Vienna 01.05.2024
Subjects
Amphetamine-Related Disorders - therapy
Animals
Central Nervous System Stimulants - pharmacology
Cocaine-Related Disorders - therapy
Deep Brain Stimulation - methods
Humans
Medicine
Medicine & Public Health
Methamphetamine
Neurology
Neurosciences
Nucleus Accumbens - drug effects
Psychiatry
Psychiatry and Preclinical Psychiatric Studies - Review Article
Substance-Related Disorders - therapy
Substance use disorders
Nucleus accumbens
Cocaine
Deep brain stimulation
Methamphetamine
Online AccessGet full text

Cover

More Information
Summary:Safe and effective therapeutics for psychostimulant use disorders remain elusive. Deep brain stimulation (DBS), which is FDA-approved for other indications, is a promising candidate for treating severe substance use disorders. We examine the clinical and preclinical evidence for DBS of the nucleus accumbens as a possible therapeutic option for cocaine and methamphetamine use disorders. Limitations of the literature to date, including the lack of females included in studies evaluating the efficacy of DBS, and new strategies to optimize brain stimulation approaches are also discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-023-02706-6